This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In AZ's push to reach industry-leading growth by 2030, confidence is key, chief financial officer Aradhana Sarin said at the J.P. With a late-stage pipeline spanning more than 120 clinical trials and a firm grasp of five major disease areas, AstraZeneca appears confident heading into 2024. | Morgan Healthcare Conference.
With Novo Nordisk, Eli Lilly and AstraZeneca leading the way, Big Pharma's sales will grow 4% annually through 2030: analysts kdunleavy Mon, 10/02/2023 - 15:19
percent between 2025 and 2030. Regional trends in the single-use technology rocking bioreactor market The report named the Americas as the leading region in the single-use technology rocking bioreactor market. A driving force for this was identified to be that the region benefits from having major bioreactor manufacturers.
billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 Leading companies in the oral solid dosage market are Catalent, Inc., Leading companies in the oral solid dosage market are Catalent, Inc., billion by 2030 appeared first on European Pharmaceutical Review.
” An analysis predicts that by 2030, 48.9% The NY Times recently reported obesity is the leading cause of mortality in the United States. Poor diet is the leading cause of mortality in the United States, causing more than half a million deaths per year. of adults in the United States will be obese, and 24.2%
An analysis predicts that by 2030, 48.9% A New York Times article said, “Poor diet is the leading cause of mortality in the U.S.” It leads to a lack of accountability. The new Inflation Bill will not reduce healthcare costs in the U.S. of adults in the United States will be obese, and 24.2% will be severely obese.
Antibody drug conjugates (ADCs) are a rapidly growing therapeutic class that leading data and analytics company GlobalData forecasts will generate more than $45bn in revenue by 2030.
As the NY Times recently reported , obesity is the leading cause of mortality in the United States. An analysis is predicting that by 2030, 48.9% Obesity costs the nation $1.72 trillion every year. In the United States, where at least 4.6 of adults in the United States will be obese and 24.2% will be severely obese. .
The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% The figure below summarises the endometriosis market growth across the 7MM from 2020 to 2030. At the end of 2030, the US will contribute approximately 81.3% of 7MM sales.
According to IPPR’s research, the UK would need to invest an extra £62 billion in 2022 to overtake Israel, the leading R&D spender. percent of GDP by 2030, to level with R&D investment in Sweden, the US and Taiwan. An extra £8.5bn in R&D would need to be invested by the government by 2030. percent to 3.4
The ATLab (Alpha Therapy Laboratory) Valenciennes in Onnaing, France, will produce lead-212 radioligand therapies. Facilitated by more than 3,000m² of floor space at the site, Orano Med shared that it is aiming to produce ten times this quantity by the end of the 2030. As a result, the project will receive public support of almost €3.8
Globally, nearly half of deaths due to cancer can be attributable to preventable risk factors, including three leading risks of smoking, drinking too much alcohol, or having a high body mass index, a new paper suggests. on cancer-related health care in 2015, and this amount is projected to grow to $246 billion by 2030—an increase of 34%.
Diabetes can lead to serious health complications like heart disease and stroke, so it’s important to take steps to avoid developing the disease if possible. The study reveals that by 2030 the ratio will decline sharply to 4 to 1 and by 2050, 3 to 1. —and a silent killer. It doesn’t have to be this way. Care Giving Crisis.
billion by 2030. This change will only lead to gastrointestinal endoscopies getting easier and saving time for both the doctors and the patient. Gastrointestinal Endoscopic Devices Market Growth (2022-2030) appeared first on MedicoReach. billion in 2021. The market is further expected to grow at a rate of 9.4% Final Thoughts.
The first industrial-scale pharmaceutical manufacturing facility for production of lead-212-based radioligand therapies has been inaugurated. This news follows the company beginning construction on a similar facility in France , which is set to produce lead-212 radioligand therapies for the European market.
A prestigious team of medical scientists has projected that by 2030, nearly one in two adults will be obese, and nearly one in four will be severely obese. The Global Burden of Disease study estimates that high sodium intake causes between 1 million and 5 million deaths per year globally” Then there is the obesity epidemic.
1ne: A new analysis predicts that by 2030, 48.9% This is going to lead to a lot of health problems and associated costs. Congress has taken decisive action to reduce drug prices while ignoring that overall healthcare spending will be a substantial part of GNP. of adults in the United States will be obese, and 24.2% percent of U.S.
Vinnova’s SEK320 million (€29 million) investment in Transfer, a two-year research project developing an AI-based quality control (QC) method using gene expression patterns to classify cells for Advanced Therapy Medicinal Product (ATMP) manufacturing , could lead to the method becoming the recommended ATMP QC method.
Eli Lilly has achieved significant gains in the past quarter, leading to it becoming the most valuable pharmaceutical company in the world, with a market cap of $420bn, surpassing Johnson & Johnson. There have been several Phase III trials for Mounjaro, with SURMOUNT-1 demonstrating a weight loss of up to 22.5%
The drug constricts blood vessels leading to a reduction in swelling and inflammation of blood vessels associated with migraine. According to GlobalData , the global migraine market will be worth $18.6bn by 2030. Rizafilm’s active ingredient is rizatriptan – a serotonin (5-hydroxytryptamine or 5-HT) receptor agonist.
With the current market outlook, both 4DMT and Sangamo are the leading developers in the Fabry disease space, and GlobalData predicts that Sangamo’s therapy will likely achieve approval and a significant market share before 4DMT’s therapy as a result of the FDA clinical hold.
It is also being developed for use in pregnant women to prevent RSV in newborns, an indication for which it looks to be in the lead after GSK was forced to halt three clinical trials while it investigates a safety signal. For children younger than five years old in the US, the infection leads to approximately 2.1
This is an effort which aims to improve access and address barriers to quality healthcare for 30 million people living in limited-resource settings annually, by 2030.
BioNTech’s chief executive Uğur Şahin said the acquisition will help “make BioNTech a technology company where AI is seamlessly integrated into all aspects of our work” as it stives to maintain its leading position in COVID-19 vaccines and continues to builds an oncology pipeline.
billion by 2030 The post France gets new sterile liquid drug manufacturing facility appeared first on European Pharmaceutical Review. The 9,500m 2 facility will harness state-of-the-art containment technologies, Baduel confirmed. The site will have approximately 100 employees and create 50 new jobs throughout 2023.
As a result, the market is expected to reach $719 billion by 2030, 1 Sigma Mostafa, PhD, Chief Scientific Officer at KBI Biopharma shared with EPR. What excites me most is the continuous infusion of new modalities, unique conjugates, and enabling technologies leading to more targeted and effective therapies. Bn by 2030.
BioNTech is anticipated to lead the market with a predicted $885 million in sales, and a 44.6 billion by 2030 BioNTech Development of mRNA-based oncology therapies for German biotech BioNTech is progressing. The global mRNA-based oncology therapy market is expected to reach $2 billion by 2029, according to GlobalData. subvariant.
By 2030, it strives to “free more than one billion people who currently require interventions against neglected tropical diseases.”. The post Neglected tropical diseases: non-profits lead the way as private sectors lags appeared first on Pharmaceutical Technology. Covid-19 strained development and treatment efforts. “The
As the NY Times reported , obesity is the leading cause of mortality in the United States. Yet the media continues to blame pharma for our healthcare woes while a new analysis is predicting that by 2030, 48.9% When a new drug is on the horizon stories, the effect, the drug will have on its stock price, not on patients.
India’s Sun Pharmaceutical has signed an agreement to acquire US biotech Concert Pharmaceuticals and its lead drug deuroxilitinib, in phase 3 testing for alopecia areata, a leading cause of hair loss. The $11.50 The report predicts that the alopecia areata market will grow to as much as $2.5
Multiple sclerosis (MS) is a primary autoimmune disease in which inflammation is a core contributor to the degeneration of the central nervous system (CNS), leading to neurological disability and affecting sensory, visual, motor, and autonomic systems. DMTs for MS have a high price tag, particularly in the US.
Within the Technology industry, Gartner predicts that Software companies will lead the way with 2022 growth of 11.5% jobs by 2030 while the workforce will only grow by 8.9M. An increase in unfilled jobs by 2030 will be great news for sales professionals and troubling news for employers trying to build their sales teams.
Between 2023 and 2030, that number is expected to grow at a compound annual growth rate of 22.6%. This may lead to better treatment outcomes, increased adherence to medication plans, and improved patient satisfaction. This approach has improved adherence rates, leading to better health outcomes. billion dollars.
Kenya’s investments, trade, and industry cabinet secretary Moses Kuria said: “This investment creates the momentum to meet the $10bn annual target under the government’s manufacturing ’20 by 30′ vision, where we plan to grow the contribution of manufacturing to GDP to 20% by the year 2030 from the current 7%.”
Yescarta for blood cancer Yescarta is targeting expansions into the first line for diffuse large B-cell lymphoma (DLBCL) and second line for follicular lymphoma in 2030. It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7
The cancer immunotherapies will mainly be provided in the context of clinical trials over the alliance, which extends out to 2030, but also covers supply of commercial therapies if approved in the interim. If successful, the partnership may also lead to manufacturing investments in the UK.
Meanwhile, the presence of a significant number of pharmaceutical and biopharmaceutical companies, and several of the leading firms worldwide puts the US and Europe ahead in the global market. Lower labour costs, presence of significant talent pool and growing domestic markets are some of the factors driving growth in the Asia-Pacific region.
GlobalData’s Blockchain Market Size, Share, Trends, and Segment Forecast to 2030 report offers insights on application of blockchain in healthcare and other key sectors. For further understanding of GlobalData's Blockchain Market Size, Share, Trends, and Segment Forecast to 2030 buy the report here.
The European Commission (EC) has launched the Healthier Together: EU Non-communicable diseases (NCDs) initiative to support EU Member States in reducing the burden of NCDs by addressing the leading causes of avoidable premature death in Europe and improving citizens’ health and well-being. Did you know, 1.7
It will also lead to greater regulatory alignment between the UK and EU, providing a huge boost to exporters, as well as improving the talent pool available to businesses and allowing for easier movement of researchers and professionals between the UK and the EU,” Brain explained.
It will operate under Orano Med and focus on creating and trialling next-generation lead-212 ( 212 Pb) radioligand therapies. Sanofi will make an equity investment of €300 million, enabling Orano Med to accelerate the development of its pipeline, leveraging the company’s capabilities in lead-212 based therapy discovery and development.
billion market by 2030, growing from a 2020 value of around $2.4 We expect a steep increase in asthma and chronic obstructive pulmonary disease in low- and middle-income countries, which will lead to demand for cost-efficient inhalation medicine and inhalers. What are the major trends in capsule development? About the author.
GlobalData’s Telehealth Market Size by Segments, Share, Trends, and Forecast, 2022-2030 report provides key insights into business strategies, trends driving the telehealth market and granular data on market segments forecast up to 2030. Buy the report here. Starting at 100 in 2020, an index over 100 is more positive.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content